BCRX
$7.31
Biocryst Pharma
($.02)
(.27%)
BCRX
Earnings Whisper ®
N/A
3rd Quarter September 2018
Consensus:  ($0.20)
Revenue:  $6.89 Mil
Tuesday
Nov 6
6:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, August 7, 2018

What do you expect when BCRX reports earnings?
Beat
Meet
Miss

Where is BCRX's stock price going from here?
Up
Flat
Down
Stock chart of BCRX
Analysts
Summary of analysts' recommendations for BCRX
Score
Grade
Pivots
Resistance
$7.73
$7.61
$7.46

$7.34

Support
$7.19
$7.07
$6.92
Tweet
Growth
Description
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
Peers
BiogenGilead SciencesBluebird BioAmgenNeurocrine BiosciencesSeattle GeneticsQiagen N.V.Bio-TechneNovavaxRepligen